AngioDynamics Inc. (NASDAQ:ANGO)’s share price shot up 1.5% during trading on Wednesday . The stock traded as high as $15.92 and last traded at $15.87, with a volume of 65,365 shares traded. The stock had previously closed at $15.63.

Separately, Zacks Investment Research raised shares of AngioDynamics from a “sell” rating to a “hold” rating in a research report on Monday, July 25th. Five analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. AngioDynamics currently has a consensus rating of “Hold” and a consensus target price of $14.10.

The stock has a 50 day moving average of $15.66 and a 200-day moving average of $12.81. The firm’s market capitalization is $585.30 million.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Wednesday, July 13th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.16 by $0.03. The business earned $93.40 million during the quarter, compared to analyst estimates of $88.64 million. The business’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.14 EPS. On average, equities research analysts forecast that AngioDynamics Inc. will post $0.63 EPS for the current fiscal year.

In other news, Director David F. Burgstahler sold 2,250,000 shares of AngioDynamics stock in a transaction that occurred on Friday, August 5th. The shares were sold at an average price of $14.62, for a total value of $32,895,000.00. Following the transaction, the director now owns 23,988 shares of the company’s stock, valued at approximately $350,704.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Avista Capital Partners Gp, Ll sold 2,241,000 shares of AngioDynamics stock in a transaction that occurred on Friday, August 5th. The stock was sold at an average price of $14.62, for a total transaction of $32,763,420.00. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in AngioDynamics stock. Morgan Stanley boosted its stake in AngioDynamics Inc. (NASDAQ:ANGO) by 6.2% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 98,634 shares of the company’s stock after buying an additional 5,728 shares during the period. Morgan Stanley owned 0.27% of AngioDynamics worth $1,198,000 at the end of the most recent reporting period.

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.